Veru Rally Follows Novo Nordisk Deal to Supply Wegovy for Phase 2b Trial

The no-cost drug supply and Novo’s first negotiation rights are being read as validation of Veru’s plan to pair enobosarm with semaglutide to protect muscle during GLP‑1 weight loss.

Overview

Veru disclosed Thursday that it signed a clinical supply agreement, dated June 2, under which Novo Nordisk will provide Wegovy at no cost to support Veru’s sponsor‑managed Phase 2b PLATEAU trial.
The PLATEAU study is testing oral enobosarm plus semaglutide in about 200 older adults with obesity, measuring percent change in body weight over 68 weeks and secondary outcomes like fat mass, physical function, and bone density.
The contract grants Novo first negotiation rights on any future commercialization of an enobosarm–GLP‑1 combination, a clause investors interpreted as strategic validation rather than an immediate revenue deal for Veru.
The SEC 8‑K disclosure triggered an extreme market reaction, with Veru shares spiking intraday (reports range from roughly 88% to over 167%) and unusually high trading volume, and analysts from Oppenheimer and Canaccord reaffirming bullish ratings.
Despite the endorsement from Novo and earlier QUALITY study signals that enobosarm can preserve lean mass during semaglutide‑driven weight loss, Veru still faces standard small‑biotech risks including trial outcomes, regulatory review, and financing needs that will determine any commercial value.